title: [Comparative evaluation of the effectiveness of different schemes of correction the portal system pressure in patients with liver cirrhosis].
abstract: The data about the complex examination and treatment of 64 patients is given. Proven the efficiency of prescribing angiotensin II receptor blocker compared with angiotensin-converting enzyme inhibitors and beta-blockers in combination with prebiotics, probiotics and L-arginine medical preparations. It is found that more manifested positive changes in indexes of intracardialy hemodynamics in patients with liver cirhhosis usage of valsartan (group III), namely: increased the left ventricular ejection fraction from (58.1 +/- 3.6) % to (65.1 +/- 1.1) % (P < 0.05), the beat index--from (28.99 +/- 2.20) ml/m2 to (36.1 +/- 3.5) ml/m2 (P < 0.05), the heart index to (3.26 +/- 0.70) l/(min2 x m2) from (2.59 +/- 0.80) l/(min2 x m2). Thus, the use of angiotensin II receptor blockers in patients with liver cirrhosis did not significantly reduce the systemic blood pressure, which must be considered in the treatment of this group of patients.
authors.forename: Ie S
authors.initials: IeS
authors.lastname: Sirchak
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006975:Hypertension, Portal / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D008103:Liver Cirrhosis / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D017082:Portal Pressure / Q000187:drug effects*; D016896:Treatment Outcome; D016277:Ventricular Function, Left / Q000187:drug effects
chemical_list: D000319:Adrenergic beta-Antagonists; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors